anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Approximately one half of all depressed psychiatric patients also meet the criteria for an anxiety disorder. Compared to people with only depression, people with both depression and panic features experience poorer psychological and social functioning, a greater risk of suicide, less response to medication and therapy treatment, and a greater risk of recurring symptoms. Because people with depression and co-occurring anxiety features do not achieve full symptom remission with either medication or therapy alone, this study will use a treatment that combines the two. A commonly used type of depression medication called a selective serotonin reuptake inhibitor (SSRI) will be combined with a specialized therapy developed to address depression with co-occurring symptoms of panic, anxiety, and avoidance. This study will also test a computer-based method of assessing mood and anxiety symptom profiles and outcomes to determine whether participants find this method acceptable and clinicians find it useful.

Participation in this study will last 20 weeks, with follow-up visits occurring 4 and 8 months after starting. Participants will be randomly assigned to receive either an individualized therapy for depression and anxiety, called interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS), or a standard therapy for depression, called brief supportive psychotherapy (BSP). All participants will complete up to 16 therapy sessions and receive a standard SSRI treatment with the medication citalopram hydrobromide. During the IPT-PS treatment, a study therapist will examine regular computer updates of depression and anxiety scores for participants and talk to them about identifying and addressing life stressors that trigger symptoms. During the BSP treatment, a study therapist will encourage participants to arrive at their own solutions by emphasizing the participants' strengths and examining what has worked in the past.

Participants will complete assessments weekly during the 20 weeks of the study intervention and at 4- and 8-month follow-up visits. These assessments will include self-report questionnaires about symptoms, medication side effects, and treatment adherence; vital sign and weight measurements; and a clinical interview. Regular assessments of medication effectiveness and side effects will occur every 1 to 4 weeks. Starting at the second study visit, participants will also complete monthly computer-based questionnaires about depression and anxiety symptoms.
AIMS: Vascular smooth muscle cells (SMCs) and their derivatives are key contributors to the development of atherosclerosis. However, studying changes in SMC gene expression in heterogeneous vascular tissues is challenging due to the technical limitations and high cost associated with current approaches. In this paper, we apply translating ribosome affinity purification sequencing to profile SMC-specific gene expression directly from tissue.
METHODS AND RESULTS: To facilitate SMC-specific translatome analysis, we generated SMCTRAP mice, a transgenic mouse line expressing enhanced green fluorescent protein (EGFP)-tagged ribosomal protein L10a (EGFP-L10a) under the control of the SMC-specific αSMA promoter. These mice were further crossed with the atherosclerosis model Ldlr-/-, ApoB100/100 to generate SMCTRAP-AS mice and used to profile atherosclerosis-associated SMCs in thoracic aorta samples of 15-month-old SMCTRAP and SMCTRAP-AS mice. Our analysis of SMCTRAP-AS mice showed that EGFP-L10a expression was localized to SMCs in various tissues, including the aortic wall and plaque. The TRAP fraction demonstrated high enrichment of known SMC-specific genes, confirming the specificity of our approach. We identified several genes, including Cemip, Lum, Mfge8, Spp1, and Serpina3, which are known to be involved in atherosclerosis-induced gene expression. Moreover, we identified several novel genes not previously linked to SMCs in atherosclerosis, such as Anxa4, Cd276, inter-alpha-trypsin inhibitor-4 (Itih4), Myof, Pcdh11x, Rab31, Serpinb6b, Slc35e4, Slc8a3, and Spink5. Among them, we confirmed the SMC-specific expression of Itih4 in atherosclerotic lesions using immunofluorescence staining of mouse aortic roots and spatial transcriptomics of human carotid arteries. Furthermore, our more detailed analysis of Itih4 showed its link to coronary artery disease through the colocalization of genome-wide association studies, splice quantitative trait loci (QTL), and protein QTL signals.
CONCLUSION: We generated a SMC-specific TRAP mouse line to study atherosclerosis and identified Itih4 as a novel SMC-expressed gene in atherosclerotic plaques, warranting further investigation of its putative function in extracellular matrix stability and genetic evidence of causality.
A patient with gastrointestinal stroma tumor (GIST) and KIT p.V559D and BRAF p.G469A alterations was referred to our institutional molecular tumor board (MTB) to discuss therapeutic implications. The patient had been diagnosed with B-cell chronic lymphocytic leukemia (CLL) years prior to the MTB presentation. GIST had been diagnosed 1 month earlier. After structured clinical annotation of the molecular alterations and interdisciplinary discussion, we considered BRAF/KIT co-mutation unlikely in a treatment-naïve GIST. Discordant variant allele frequencies furthermore suggested a second malignancy. NGS of a CLL sample revealed the identical class 2 BRAF alteration, thus supporting admixture of CLL cells in the paragastric mass, leading to the detection of 2 alterations. Following the MTB recommendation, the patient received imatinib and had a radiographic response. Structured annotation and interdisciplinary discussion in specialized tumor boards facilitate the clinical management of complex molecular findings. Coexisting malignancies and clonal hematopoiesis warrant consideration in case of complex and uncommon molecular findings.
Mixed Salts of a Single Entity Amphetamine Product has a high potential for abuse and misuse. The use of Mixed Salts of a Single Entity Amphetamine Product exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Mixed Salts of a Single Entity Amphetamine Product can be diverted for non-medical use into illicit channels or distribution (see DRUG ABUSE AND DEPENDENCE, Abuse). Misuse and abuse of CNS stimulants, including Mixed Salts of a Single Entity Amphetamine Product, can result in overdose and death (see OVERDOSAGE), and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.

Before prescribing Mixed Salts of a Single Entity Amphetamine Product, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store amphetamine sulfate in a safe place, preferably locked, and instruct patients to not give Mixed Salts of a Single Entity Amphetamine Product to anyone else. Throughout Mixed Salts of a Single Entity Amphetamine Product treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
OBJECTIVES: The aim of this study is to investigate the neurovascular bundle (NVB) as a potential orthodontic relapse factor. The mechanical properties and the forces generated in the NVB after orthodontic extrusion are explored.
MATERIALS AND METHODS: Six NVBs branching from the inferior alveolar nerve to the apices of the mandibular canines and premolars of mature pigs were harvested. Stress relaxation tests were conducted. A standard linear solid model (SLS) was utilized to simulate the orthodontic extrusion of a single rooted tooth with NVB length and cross-sectional diameter of 3.6 and 0.5 mm, respectively, so the NVB was stretched 10% and 20% of its original length. The maximum force within the NVB was then calculated.
RESULTS: Based on our data, the average Young's modulus before relaxation (   E 0    ), after relaxation (   E P    ) and the difference between Young's moduli before and after relaxation (   E S    ) were 324 ± 123, 173 ± 73 and 151 ± 52 kPa, respectively. The theoretical force within the NVB stretched to 10% and 20% strain was 3 and 5 mN, respectively.
CONCLUSION: The data from our study indicate that the NVB exhibits stress relaxation, a characteristic trait of viscoelastic materials. SLS model simulation predicted residual forces around 5 mN for elongation up to 20%. We observed strain hardening with additional elongation, which has the potential to cause forces to increase exponentially. Therefore, tensile forces in the NVB should not be ruled out as a contributor to orthodontic relapse, especially in adult patients who may have decreased adaptability of their NVB. Further preclinical and clinical models should be developed to further clarify what is the contribution of the NVB to orthodontic relapse.
Pericarditis as an inflammatory heart disease is rarely discussed in the cardiology community. The latest European guidelines on pericarditis were published in 2015, and Russian clinical guidelines are dated 2022. However, in recent years, a number of publications have appeared that have forced the scientific community to take a fresh look at this problem. This is mainly due to a change in the paradigm of the treatment of idiopathic recurrent pericarditis (IRP) registered in the Russian Federation as a rare (orphan) disease. According to most experts, IRP is an underestimated cardiac disease, which, due to the lack of specific symptoms and the physicians' alertness regarding the IRP diagnostics, is rarely the subject of scientific discussions. The issues of diagnosis and therapy of IRP in light of the latest reports became the matter under discussion for a group of leading Russian experts chaired by Corresponding Member of the Russian Academy of Sciences, Professor G.P. Arutyunov.
The present invention relates to a compatible composition of a masticinic acid and amyrrh terpene. A masticinic acid-based compound and a myrrh terpene-based compound are used as basic active ingredients, and a pharmaceutical composition having significant anti-inflammatory and analgesic effects is used in a compatible way. The effect so obtained is superior to that of a masticinic acid and a myrrh terpene alone. Further disclosed is a preparation method therefor. The present invention also relates to use of the pharmaceutical composition in chronic pain diseases such as inflammatory pain, cancerous pain, neuropathic pain. The pharmaceutical composition is used as an analgesic agent, and has the advantages of long-term use without dependence or withdrawl reactions in addition to having anti-inflammatory and anti-tumor effects.
PROBLEM TO BE SOLVED: To obtain a percutaneous absorption preparation which maintains the concentration of an antagonist in blood, reduces adverse drug reactions, permits the expansion of adaptation diseases and is useful as a wound therapeutic agent or the like by including a specific antagonist. SOLUTION: This percutaneous absorption preparation is obtained by including (A) thromboxane A2 receptor antagonist. The ingredient A is dissolved or dispersed at a concentration of 1-100 mg in 1 g of a base. The ingredient A is preferably a compound of the formula, its salt or their hydrates. The above preparation is preferably prepared by the use of an aqueous or oily base. As the aqueous base, a lower alcohol (e.g. isopropanol), a polyol (e.g. propylene glycol) or purified water is preferably used. As the oily base, a lipophilic alcohol (e.g. benzyl alcohol) or a higher fatty acid ester is preferably used. The above preparation is preferably used as a therapeutic agent for wound, allergic rhinitis, asthma, antithrombus or myocardial infarction.
The aim of this experiment was to investigate the effects of Ageratina adenophora on the expression of epithelium tight junction proteins and inflammatory factors in the rumen of goats. Twelve goats were randomly divided into three groups. The first group was the blank control group (n = 3, C) which was fed normal diet. The second group was fistulas control group (n = 3, RFC), which was fitted with rumen fistulas, and fed normal diet. The third group was the A. adenophora test group (n = 6, AA), which was fitted with rumen fistulas and fed a mixture of 60% of normal diet and 40% of A. adenophora grass powder. The feeding experiment lasted for 90 d, after which all goats were sacrificed and samples were collected from the rumen dorsal sac and ventral sac. The relative expression of mRNA of inflammatory factors in the rumen epithelium (tumor necrosis factor alpha [TNF-α], interferon gamma [IFN-γ], interleukin 1 beta [IL-1β], IL-2, IL-4, IL-6, and IL-10) and tight junction protein genes (occludin, claudin-1, and ZO-1) was measured by quantitative real-time fluorescence PCR. Expression of tight junction proteins in the rumen epithelium was measured by Western blot. A correlation was established between the expression of inflammatory factors and tight junction protein genes using Graph Pad Prism. The results showed that A. adenophora caused a significant increase in the mRNA expression levels of TNF-α, IFN-γ, IL-1β, IL-2, IL-6, and IL-10 in the rumen epithelial (P < 0.05 or P < 0.01). The expression of tight junction proteins at both gene and protein levels was significantly decreased (P < 0.05 or P < 0.01). Furthermore, the correlation analysis revealed that the changes in tight junction protein expression in the test group were closely related to the upregulation of the expression of inflammatory factors TNF-α and IFN-γ in rumen epithelial cells. In conclusion, the expression of inflammatory factors was increased and the expression of tight junction proteins was decreased in goats after feeding on A. adenophora, which caused some damage to the rumen epithelium.
PROBLEM TO BE SOLVED: To obtain a detergent compsn. which exhibits good foaming properties, detergency, and foam qualities during cleaning and is excellent in the feeling of refreshment after rinsing by imcoporating a potassium salt of a higher fatty acid, an alkyldimethylaminoacetic acid betaine, and a high-polymn.-degree polyethylene glycol into the same. SOLUTION: This compsn. contains 5-30wt.% potassium salt of a higher fatty acid, 2-20wt.% alkyldimethylaminoacetic acid betaine, and 0.0005-1wt.% high-polymn.-degree polyethylene glycol. The synergistic action of the potassium salt and the betaine provides a thickening effect, giving a stable liq. with a suitably high viscosity even without using a gelatinizing agent. The synergistic action also improves the detergency of the compsn. and enables the inhibition of occurrence of soap scum.
Subjects with clinically confirmed or suspicion of kidney/renal pelvis cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
An intrinsic factor preparation of enhanced potency is prepared by extracting hog pyloric mucosa with an aqueous acidic solution at pH 2.0 to 5.0 and fractionating the so-formed extract by adding ethanol (or an aliphatic alcohol or ketone having less than 5 carbon atoms) until the concentration is between 20 and 60 per cent (preferably 45 to 55 per cent), by volume to obtain a precipitate of enhanced intrinsic factor potency.  The pyloric mucosa may be comminuted, if desired after being frozen to prevent loss of activity.  The extraction may be carried out at a temperature below 15 DEG  C., preferably below 5 DEG  C., the pH being adjusted by means of hydrochloric, sulphuric, phosphoric, lactic or citric acid.  In the fractionation step the pH may be adjusted to between 4 to 6 (preferably 4.5 to 5.5) by means of sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium carbonate or potassium carbonate.  In addition to ethanol, methanol, acetone and methyl ethyl ketone are specified as liquid organic precipitating agents. The ionic strength during the fractionation should be less than 0.15, and the temperature below 0 DEG  C., e.g. -5 DEG  C.  The precipitate may be separated, e.g. by centrifugal means, dissolved in ice-cold water, clarified and lyophilized.  The examples give detailed accounts of the manner of carrying out the process of the invention.  Specification 745,473 is referred to.
The invention relates to the technical field of extracting active components of a traditional Chinese medicine. The prior extracting methods for the effective ingredients of cordyceps militaris are realized mostly through steaming and cooking, refluxing, soxhlet extraction and the like, and the required temperature is high, the time is long, and the loss of active ingredients is large. The method provided by the invention uses ultrasound to process the cordyceps militaris and a culture medium, is simple, convenient, time-saving and pollution-free, and is easy to scale up. The adopted technical key points mainly comprise repeated times of ultrasound treatments on the cordyceps militaris and the culture medium under the condition that the temperature is between 20 and 60 DEG C, the power is between 50 and 100 watts, and the pH value is between 1.0 and 10.0 so that the needed active ingredients are completely dissolved in a solvent. After centrifugation, the extract is a clear and transparent liquid which has high content of medicinal components and obvious effect on fungi inhibition. The method has simple process, is time-saving, and is easy for mass production without environmental pollution. The obtained products can be applied to the aspects of manufacturing pharmaceutical products, fresh-keeping agents, drug sundries and the like, and various products can be obtained through research and development.
FIELD: pharmaceutical industry. SUBSTANCE: dosaged form is made as a tablet or granule. Form has 10-carboxymethyl-9-acridanone ammonium or N-methylglucaminic salt as an active component and special additions. Dosaged form is covered by protective acid-resistant coating made of shellac or acetylphthalyl cellulose. Tablets and granules are used for prophylaxis and treatment of viral diseases. EFFECT: improved quality of form, enhanced antiviral activity. 2 cl, 11 tbl
OBJECTIVE: To assess growth parameters in adolescents and children with type 1 diabetes mellitus, and the factors influencing their growth.
METHODS: The case-control study was conducted from February to December 2020 at the Endocrine Outpatient Clinic of the Central Child Teaching Hospital of Paediatrics, Baghdad, Iraq, and comprised patients aged 2-16 years who had type 1 diabetes for at least a year. The patients formed group A, while healthy controls matched for age and gender from different schools and kindergartens formed group B. Weight, height and body mass index of all the subjects in both groups were measured and worked out, and the values were compared. Data was analysed using SPSS 25.
RESULTS: Of the 192 subjects, 96(50%) were in each of the 2 groups; 50(52.1%) girls and 46(47.9%) boys in group A, and 58(60.4%) girls and 38(39.6%) boys in group B. The overall mean age was 9.66±3.26 years. Group A children had significantly lower mean height, weight and body mass index Z scores compared to group B (p=0.001). The height Z score of group A children was significantly inversely associated with age, duration of disease, and glycated haemoglobin level (p=0.001), while the weight Z score was significantly inversely correlated with age and glycated haemoglobin (p=0.001). The body mass index Z score of group A was significantly inversely associated with age and glycated haemoglobin level (p<0.05).
CONCLUSIONS: Children with type 1 diabetes mellitus had significantly lower mean height, weight and body mass index Z scores compared to their counterparts in the control group. Pubertal age group, poor glycaemic control, longer disease duration, and using conventional insulin regimen were the factors affecting growth parameters.
Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
Few existing reports have investigated the copy number variants (CNVs) in fetuses with central nervous system (CNS) anomalies. To gain further insights into the genotype-phenotype relationship, we conducted chromosomal microarray analysis (CMA) to reveal the pathogenic CNVs (pCNVs) that were associated with fetal CNS anomalies. We enrolled 5,460 pregnant women with different high-risk factors who had undergone CMA. Among them, 57 subjects with fetal CNS anomalies were recruited. Of the subjects with fetal CNS anomalies, 23 were given amniocentesis, which involved karyotype analysis and CMA to detect chromosomal abnormalities. The other 34 cases only underwent CMA detection using fetal abortive tissue. In this study, we identified five cases of chromosome aneuploid and nine cases of pCNVs in the fetuses, with a chromosomal aberration detection rate of 24.56% (14/57). In the 23 cases that were given both karyotype and CMA analysis, one case with trisomy 18 was detected by karyotyping. Moreover, CMA revealed a further three cases of pCNVs, including the 1p36.33p36.31, 7q11.23, and 1q21.1q21.2 microdeletions, with a 13.04% (3/23) increase in CMA yield over the karyotype analysis. Additionally, three cases of trisomy 13, one case of trisomy 21, and six cases of pCNVs were detected in the other 34 fetuses where only CMA was performed. Furthermore, a higher chromosomal aberration detection rate was observed in the extra CNS anomaly group than in the isolated CNS anomaly group (40.91% vs 14.29%). In conclude, several pathogenic CNVs were identified in the fetuses with CNS anomalies using CMA. Among the detected CNVs, ZIC2, GNB1, and NSUN5 may be the candidate genes that responsible for fetal CNS anomalies. Our findings provides an additional reference for genetic counseling regarding fetal CNS anomalies and offers further insight into the genotype-phenotype relationship.